Corcept Therapeutics Incorporated - estatísticas financeiras trimestrais (NASDAQ:CORT) | MetaTrader

Abrir gráfico completo

Corcept Therapeutics Incorporated

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Notícias

Lifyorli da Corcept reduz risco de morte em 35% no câncer de ovário

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Executivo da Corcept Therapeutics vende US$ 819 mil em ações

Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade) (NASDAQ:CORT)

Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

Wolfe Research eleva classificação da Corcept Therapeutics após aprovação do FDA

FDA aprova Lifyorli da Corcept para tratamento de câncer de ovário

Ações da Corcept Therapeutics disparam após aprovação de medicamento contra câncer pela FDA

Why Corcept's Ovarian Cancer 'Hail Mary' Might Actually Land (NASDAQ:CORT)

Ações da Corcept Therapeutics sobem após compra de ações por diretor